CEO & CO-FOUNDER
Mr. Alleruzzo, a co-founder of Immunophotonics, is a BioEngineer with an MBA. His background includes basic research experience before transitioning into business roles in the healthcare industry. Additional board service roles include the NIH Midwest Biomedical Accelerator Consortium, Missouri Biotechnology Association and American Cancer Society. 10+ years life sciences industry experience.

CHIEF INNOVATION OFFICER, PRESIDENT & CO-FOUNDER
Dr. Hode is a co-founder of Immunophotonics and has 30 years’ experience in life science, both in industry and academia. He received his PhD from Stockholm University, Sweden, focusing on analytical development, did a post-doc in the USA, and subsequently returned to industry with Immunophotonics.

VP INTERNATIONAL BUSINESS DEVELOPMENT
MANAGING DIRECTOR - IPS BIOPHARMA AG (Swiss Subsidiary)
Dr. Visarius is the Vice President of Business Development at Immunophotonics and Managing Director of the Swiss subsidiary IPS Biopharma AG. She joined the company in 2015 after 8 years as an entrepreneur where she worked with global leaders in health care as well as start-ups to facilitate market access of innovative medical technologies.

VP SCIENCE AND RESEARCH
Dr. Lam received his Bachelor of Science degree in Molecular and Cellular Biology from John Hopkins University and his Ph.D. in Immunology from Washington University. He also acquired a master’s degree in Biotechnology Enterprise and Entrepreneurship from Johns Hopkins University. His primary role at Immunophotonics is to oversee the research and development of the company’s assets..

VP OF REGULATORY & CLINICAL AFFAIRS
Dr. Beatty holds a Ph.D. in Chemistry/ Biochemistry from the University of Missouri - Kansas City. She has nearly 25 years of experience in the formulation and execution of scientific and regulatory strategies for drug, biologic, and device development programs. Dr. Beatty has extensive experience in leading development teams from discovery to post-approval.

GENERAL COUNSEL & DIRECTOR OF OPERATIONS
Mr. Hurst joined Immunophotonics in 2019 after working in private practice, where he provided outside general counsel services to numerous startups and small businesses. At Immunophotonics, he uses his dual background as a J.D./M.B.A. to oversee the company’s legal matters, operations management, and IP portfolio.

SENIOR VP OF CMC
Dr. Raker has over 30 publications and patents and holds a B.S. in Chemistry from Utica College of Syracuse University and a Ph.D. in Organic Chemistry from The Pennsylvania State University. Dr. Raker joined Immunophotonics in 2014 and oversees all CMC operations for the company.

VP ASIAN BUSINESS DEVELOPMENT
Mr. Jiao acquired his master’s degree in Financial Economics and worked for GlenMartin HQ as VP of strategic business development. In 2012 he joined Immunophotonics as VP of Asian business development. He set up the Chinese subsidiary Tianjin Yinuo.

PRINCIPAL CHEMIST
Dr. Delawder received her Bachelor of Science degree in Chemistry from Drury University and her Ph.D. in Polymer Chemistry from Washington University in St. Louis. Prior to joining Immunophotonics, her research focused primarily on understanding the self-assembly behavior of redox-responsive, unimolecular polymers. Her extensive knowledge of polymer characterization techniques and synthesis enables our team to continue developing and managing new and existing drug products.

EXECUTIVE DIRECTOR OF CMC
Dr. Chaber received his Bachelor of Science degree in Chemistry at the University of Missouri-St. Louis and his Ph.D. degree in Pharmaceutical Analytical Chemistry from the School of Pharmacy at Purdue University. Dr. Chaber has over 30 years of experience in the pharmaceutical industry focusing on chemical manufacturing controls (CMC) drug development.

RESEARCH SCIENTIST
Mr. Wong joined Immunophotonics in June 2021 as a research scientist. He received his Bachelor of Science degree in Biology and in Environmental Studies from Saint Louis University with research experiences in immunology and pharmacology. In the lab, he aides in day-to-day operations for the Research & Development team.

EXECUTIVE ASSISTANT
Mrs. Kemper joined Immunophotonics in 2020. With over 20 years of experience in office executive assistant and office management positions, she skillfully manages a variety of administrative tasks, provides administrative support, and many other miscellaneous and challenging activities. She handles the details that facilitate a smooth-running program on a day-to-day basis.

CHAIRMAN
Dr. Sandage has over 35 years of experience in the pharmaceutical industry in drug development and senior management and currently Managing Director of the Riney Family Foundation and General Partner in Cultivation Capital Life Sciences Fund II.

BIOGENERATOR
Charlie is a Senior Vice President of BioGenerator, a seed stage investment group. He has extensive R&D experience having 10 years’ experience working at large pharmaceutical companies.

DIRECTOR
Jonathan has a distinguished career in the pharmaceutical industry as well as academia. He was the founding Chairman of the Board and central to the establishment of the Innovative Medicines Initiative.

DIRECTOR
Miguel served as Chief Technology Officer and Executive Vice President of Hyland Software Inc. He has a bachelor’s degree in computer engineering from Case Western Reserve University. Mr. Zubizarreta is a recognized authority in ECM and has been a speaker or panel member at many different annual conferences for the last decade.

INVENTOR
Wei is a co-inventor of inCVAX (IP-001) and a co-founder of Immunophotonics, Inc. His research focuses on laser medicine, with a special emphasis on ablation-based immunotherapy for metastatic cancers.

CHIEF INNOVATION OFFICER AND PRESIDENT
Dr. Hode is a co-founder of Immunophotonics and has 30 years’ experience in life science, both in industry and academia. He received his PhD from Stockholm University, Sweden, focusing on analytical development, did a post-doc in the USA, and subsequently returned to industry with Immunophotonics.

CEO
Mr. Alleruzzo, a co-founder of Immunophotonics, is a BioEngineer with an MBA. His background includes basic research experience before transitioning into business roles in the healthcare industry. Additional board service roles include the NIH Midwest Biomedical Accelerator Consortium, Missouri Biotechnology Association and American Cancer Society. 10+ years life sciences industry experience.

CLINICAL DEVELOPMENT
Daniel has conducted clinical trials on more than 200 antineoplastic and biologic agents. He currently serves as Distinguished Professor and Executive Vice President of the Translational Genomics Research Institute.

CLINICAL DEVELOPMENT
Richard is currently a Professor at the Pathology Department at UC Davis. He received his undergraduate degree at Harvard College, his medical degree at the University of Michigan and his pathology training at Washington University, St. Louis.

CLINICAL DEVELOPMENT
Mark received his medical degree from Texas Tech University School of Medicine and his specialty certificate in internal medicine from the University of Alabama. He completed his scientific fellowship in tumor biology at the MD Anderson Cancer Center.

BUSINESS ADVISOR
Richard has over 25 years’ experience in high-level positions within the medical device sector, with a focus on ablation devices. He currently serves as a board member and company president of Sanarus Technologies, Inc.

NON-CLINICAL AND TRANSLATIONAL DEVELOPMENT
David has deep expertise in target-based drug discovery/development and personalized molecular diagnostics in inflammation and oncology. He has served as a consultant for numerous other companies, VC and investment firms, and as an SAB member.

CLINICAL DEVELOPMENT - INTERVENTIONAL RADIOLOGY
Rolf is an interventional radiologist in practice for 16 years at Scottsdale Medical Imaging, Ltd., in Scottsdale, Arizona. His particular area of interest is interventional oncology with procedures including percutaneous ablation, chemoembolization, and radioembolization.

CLINICAL DEVELOPMENT
Robert has completed over 15 prospective clinical trials and was principal investigator of 1 Humanitarian Device Exemption (HDE), 2 Investigation New Drugs (IND), and 3 Investigational Device Exemption (IDE) trials.

CULTIVATION CAPITAL
David earned a doctorate degree in Molecular Biology and a bachelor’s degree in Biology from Emory University in Atlanta. He is a General Partner at Cultivation Capital and previously served as the Chief Scientific Officer of Sigma-Aldrich Corporation.